Benzinga - by Vandana Singh, Benzinga Editor.
Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN), engaging with the company on its strategic direction amid leadership changes and the evolving status of its hemophilia treatment, Roctavian.
The hedge fund has invested over $1 billion in BioMarin, which specializes in rare genetic diseases and has a market capitalization of approximately $16 billion.
Elliott's involvement comes at a critical time for BioMarin as it navigates a CEO transition and adjusts its strategy for Roctavian, whose sales forecast has been revised downward from $50 million-$150 million to less than $10 million, prompting analysts to temper their short-term expectations while maintaining a long-term positive outlook.
Amidst these developments, BioMarin's stock has experienced a notable decline, dropping 24% year-to-date and trailing behind the sector benchmark, the iShares Biotechnology ETF (NASDAQ: IBB), which has seen an 8.6% decrease in the same period, Reuters noted.
This disparity has triggered conversations about BioMarin's potential as an acquisition target, given the unique positioning of its complex-to-manufacture therapies and exemption from Medicare drug pricing negotiations.
Recently, BioMarin announced that Jean-Jacques Bienaime will step down as CEO, making way for Alexander Hardy of Genentech, effective December 1.
William Blair suggests that although the precise objectives of the firm's activism are not yet known, it wouldn't be unexpected for the activist to advocate for either a more streamlined approach to the company's research and development expenditures, which include seven clinical candidates, or a complete sale of the company.
The scrutiny is anticipated to intensify, particularly in how the firm addresses investment needs in ongoing research areas, like the company's initiatives in skeletal dysplasia and growth disorders, which are essential for its portfolio.
Price Action: BMRN shares closed up 12.10% at $85.49 on Tuesday.
Latest Ratings for BMRN
| Feb 2022 | Piper Sandler | Maintains | Overweight | |
| Nov 2021 | Credit Suisse | Maintains | Outperform | |
| Nov 2021 | Morgan Stanley | Maintains | Equal-Weight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.